Journal of Experimental & Clinical Cancer Research 2009, 28:135 http://www.jeccr.com/content/28/1/135 References 1. Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin 2005, 55:74-108. 2. Giovannucci E: Epidemiologic characteristics of prostate can- cer. Cancer 1995:1766-77. 3. Bosland MC: The role of steroid hormones in prostate can- cerogenesis. J Natl Cancer Inst Momogr 2000, 27:39-66. 4. Diamandis EP, Yu H: Does prostate cancer start at puberty? Clin Lab Anal 1996, 10(6):468-9. 5. Barba M, Terrenato I, Schünemann H, Fuhrman B, Sperati F, Teter B, Gallucci M, D'Amato A, Muti P: Indicators of Sexual and Somatic Development and Adolescent Body Size in Relation to Pros- tate Cancer Risk: Results from a Case-control Study. Urology 2008, 72(1):183-7. 6. Carruba: Estrogens and Mechanisms of Prostate Cancer Pro- gression. Ann N Y Acad Sci 2006, 1089:201-7. 7. Bosland MC, Ford H, Horton LI: Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague- Dawley Hsd:SD rats treated with a combination of testoster- one and estradiol-17β or diethylbestrol. Carcinogenesis 1995, 16:1311-7. 8. Ho SM, Lane K: Sex hormone-induction and dietary modula- tion of prostatic adenocarcinoma (PA) in animal models. Urol Oncol 1996, 2:110-5. 9. Ayala AG, Roj Y: Prostatic intraepithelial neoplasia: recent evi- dence. Arch Pathol Lab Med 2007, 131(8):1257-31. 10. Lotinum P, West K, Gibson KJ, Turner RT: Tissue-selective effects of continuous release of 2-hydrohyestrone and 16α-hydrox- yestrone on bone, uterus and mammary gland in ovariector- ized growing rats. J Endocrinol 2001, 170:165-174. 11. Suto A, Bradlow H, Wong GY, Osborne MP, Telang NT: Experi- mental down-regulation of intermediate biomarkers of car- cinogenesis in mouse mammary epithelial cells. Breast Cancer Res Treat 1993, 27:193-202. 12. Telang NT, Suto A, Wong GY, Osborn MP, Bradlow HL: Induction by estrogen metabolite 16α-OHE1 of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 1992, 84:634-8. 13. Muti P, Westerlind K, Wu T, Grimaldi T, De Berry J, Schünemann H, Freudenheim JL, Hill H, Carruba G, Bradlow L: Urinary estrogen metabolites and prostate cancer: a case-control study in the United States. Cancer Causes Control 2002, 13(10):947-55. 14. Trevisan M, Dorne J, Falkner K, Russell M, Ram M, Muti P, Freuden- heim JL, Nochajascki T, Hovay K: Drinking pattern and risk of non-fatal myocardial infarction: a population-based case- control study. Addiction 2004, 99:313-22. 15. Thompson IM, Ankerst D, Chi C, Lucia MS, Goodman PJ, Crowly JJ, Parnes HL, Coltman CA: Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006, 98(8):529-34. 16. Meilahn EN, De Stavola B, Allen DS, Fentiman I, Bradlow HL, Sepkovic DW, Kuller LH: Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 1998, 78(9):1250-5. 17. Andersson SO, Adami H, Bergström R, Wide L: Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study. Br J Cancer 1993, 1993(1):97-102. 18. Signorello LB, Tzonou A, Mantzoros CS, Lipworth L, Lagiou P, Hsieh C, Stampfer M, Trichopoulos D: Serum steroids in relation to prostate cancer risk in a case-control study (Greece). Cancer Causes Control 1997, 8(4):632-6. 19. Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann HJ: Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous throm- boembolism in patients with cancer: a cochrane systematic review. J Exp Clin Cancer Res 2008, 18(27):21. 20. Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Bdair F, Schünemann HJ: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a system- atic review. Cancer 2008, 113(7):1685-94. 21. Akl EA, Terrenato I, Barba M, Sperati F, Sempos EV, Muti P, Cook DJ, Schünemann HJ: Low-molecular-weight heparin vs unfraction- ated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis. Arch Intern Med 2008, 168(12):1261-9. 22. Capurso G, Schünemann H, Terrenato I, Moretti A, Koch M, Muti P, Capurso L, Delle Fave G: Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for dif- ferent exposure categories. Aliment Pharmaco Ther 2007, 26(8):1089-99. 23. Higgins JTS: Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21(11):11539-58. 24. Yang L, Gaikwad N, Meza J, Cavalieri EL, Muti P, Trock B, Rogan EG: Novel Biomarker for Risk of Prostate Cancer: results from a case-control study. Prostate 2009, 69(1):41-8. 25. Gann PH, Hennekens C, Ma J, Longcope C, Stampfer MJ: Prospec- tive study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996, 88(16):1118-26. 26. Hsing A: Hormones and prostate cancer: what's next? Epide- miol Rev 2001, 23(1):42-58. 27. Zhu BT, Coney A: Functional role of estrogen metabolism in target cells: reviews and perspectives. Carcinogenesis 1998, 19:1-27. 28. Lewis JS, Thomas T, Klinge CM, Gallo MA, Thomas T: Regulation of cell cycle and cyclins by16alpha-hydroxyestrone in MCF-7 breast cancer cells. J Mol Endocrinol 2001, 27:293-307. 29. Gupta M, McDougal A, Safe S: Estrogenic and antiestrogenic activities of alpha- and 2-hydroxyestrone of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J Steroid Bio- chem Mol Biol 1998, 67:413-9. 30. Bradlow HL, Sepkovic D, Telang NT, Osborne MP: Multifunctional aspects of the action of indol-3-carbinol as an antitumor agent. Ann NY Acad Sci 1999, 889:204-13. 31. Teas J, Cunningham J, Fowke JH, Nitcheva D, Kanwat CP, Boulware RJ, Sepkovic DW, Hurley TG, Herbert JR: Urinary estrogen metabolites, prostate specific antigen, and body mass index among African-American men in South Carolina. Cancer Detect Prev 2005, 29(6):494-500. 32. Osborne MP, Bradlow H, Wong GYC, Telang NT: Upregulation of estradiol C16α-hydroxylation in human breast tissue: a potential biomarker of breast caner risk. J Natl Cancer Inst 1993, 85:1917-1920. 33. Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC: A pilot study of urinary estrogen metabolites (16alpha-OHE1 and 2-OHE1) in postmenopausal women with and without breast cancer. Environ Health Perspect 1997, 105(S3):601-5. 34. Kabat GC, Chang C, Sparano JA, Sepkovie DW, Hu XP, Khalil A, Rosenblatt R, Bradlow HL: Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 1997, 6(7):505-9. 35. Muti P, Bradlow H, Micheli A, Krogh V, Freudenheim JL, Schünemann HJ, Stanulla M, Yang J, Sepkovic DW, Trevisan M, Berrino F: Estro- gen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopau- sal and postmenopausal women. Epidemiology 2000, 11(6):635-40. Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime." Sir Paul Nurse, Cancer Research UK Your research papers will be: available free of charge to the entire biomedical community peer reviewed and published immediately upon acceptance cited in PubMed and archived on PubMed Central yours — you keep the copyright Submit your manuscript here: http://www.biomedcentral.com/info/publishing_adv.asp BioMedcentral Page 8 of 8 (page number not for citation purposes)